News
BIO
275.60
-0.94%
-2.61
SPY ETF Update, 4/25/2024  
TipRanks · 18h ago
Danaher gains as Q1 results exceed expectations
Danaher (DHR) shares added ~9% premarket Tuesday after the company topped Street forecasts with its Q1 2024 financials. The life sciences toolmaker reported $5.8B in revenue for the quarter with a 3% YoY decline in sales.
Seeking Alpha · 2d ago
BIO-RAD LABORATORIES INC REPORTS 8.99% PASSIVE STAKE IN ONCOCYTE CORP AS OF APRIL 15 - SEC FILING
Reuters · 3d ago
Goldman’s debt issuers stocks basket
Seeking Alpha · 3d ago
Weekly Report: what happened at BIO last week (0415-0419)?
Weekly Report · 3d ago
New Strong Sell Stocks for April 19th
NASDAQ · 6d ago
Thursday Sector Laggards: Technology & Communications, Healthcare
NASDAQ · 04/18 18:38
96% Of S&P 500 Stocks Show Upside Potential Vs. Street Estimates: Which Offers The Best Opportunity?
April has marked the bleakest month for the U.S. Stock market since September 2023. The S&P 500 index has fallen by 3.7% this month, with 480 out of 500 companies in the index trading at lower market values compared to analysts’ price targets. The top 5 contrarian stocks within the S&p 500 index exhibit the most pronounced gap between current prices and median targets.
Benzinga · 04/18 17:01
Bio-Rad Laboratories (BIO) to Post Q1 Earnings: What Awaits?
NASDAQ · 04/18 14:03
Press Release: Bio-Rad to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
Bio-Rad to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024. Bio-Rad is a global leader in life science research and clinical diagnostics products. The company will report its financial results for the first quarter of 2024. Management will discuss these results in a conference call that day.
Dow Jones · 04/18 13:06
Bio-Rad Laboratories (NYSE:BIO) Has A Pretty Healthy Balance Sheet
Bio-Rad Laboratories, Inc. Has US$1.19b in debt on its balance sheet. The company has more cash than debt, and has net cash of US$417.7m. Its debt levels are a concern, but the company has a healthy balance sheet for the long-term. Bio- Rad Laboratories's EBIT has tanked 25% in the last 12 months. The business needs free cash flow to pay off debt.
Simply Wall St · 04/18 10:59
Commit To Purchase Bio-Rad Laboratories At $185, Earn 1.3% Annualized Using Options
NASDAQ · 04/17 15:40
Bio-Rad (BIO) Hurt by Softness in BioPharma and Competition
NASDAQ · 04/16 14:56
Weekly Report: what happened at BIO last week (0408-0412)?
Weekly Report · 04/15 09:29
Bio-Rad: A Lackluster Picks-And-Shovels Life Science Company With A Key Investment Kicker
Bio-Rad is a "picks and shovels" company in the life sciences industry but lacks standout growth, margins, or returns. The company saw double-digit declines in its Life Sciences segment in the last two quarters. Bio-Rad's holdings in Sartorius bring significant value to the company, but it's hard to love the stock on its own.
Seeking Alpha · 04/14 05:23
Oncocyte stock rallies 90% post-market on Bio-Rad partnership
Oncocyte announced a partnership with Bio-Rad for the global launch of its GraftAssure assay for organ transplant monitoring. The product is slated to be launched in Q2 to select academic transplant centers in the US and EU. Oncocyte stock rallies 90% post-market on Bio- Rad partnership.
Seeking Alpha · 04/11 22:15
Oncocyte, Bio-Rad Partner on Global Launch of Transplant Assay
Oncocyte and Bio-Rad agree to a partnership agreement to commercialize the research use only GraftAssure assay. The product is expected to launch in the second quarter to a select group of academic transplant centers in the U.S. And EU. The companies will co-market the assay in the US and Germany. Oncocyte uses donor-derived cell-free DNA to assess organ health.
Dow Jones · 04/11 22:11
BUZZ-OncoCyte jumps on partnership with Bio-Rad
OncoCyte shares rise 93.3% to $5.73 in extended trading. Company announces partnership with Bio-Rad for blood-based organ transplantation monitoring test GraftAssure. Shares of diagnostics company up 18.6% year-to-date.
Reuters · 04/11 22:09
Oncocyte Announces Partnership Agreement With Bio-Rad Laboratories On Global Launch Of Transplant Assay; Bio-Rad Expects To Make Equity Investment In Support Of Deal
New product expected to launch in Q2 2024 to a select group of academic transplant centers in the US and EU. Bio-Rad and Oncocyte will co-market the assay in the U.S. And Germany. The company has been granted exclusive global distribution and commercial rights.
Benzinga · 04/11 21:32
ONCOCYTE CORP - BIO-RAD EXPECTS TO MAKE EQUITY INVESTMENT IN SUPPORT OF DEAL
Reuters · 04/11 21:30
More
Webull provides a variety of real-time BIO stock news. You can receive the latest news about Bio Rad Labs Inc through multiple platforms. This information may help you make smarter investment decisions.
About BIO
Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. The Company operates through two segments: Life Science and Clinical Diagnostics. Its Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes and food testing regimes. The Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are primarily sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.